Jan N. Lycke

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 128 publications

Calprotectin reveals distinct innate immune signatures in NMOSD, MOGAD, and multiple sclerosis.

Calprotectin reveals distinct innate immune signatures in NMOSD, MOGAD, and multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: January 17, 2026

Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months.

Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months.

Journal: Journal of neurology

Published: January 16, 2026

Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis.

Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis.

Journal: European journal of neurology

Published: January 09, 2026

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Journal: Annals of clinical and translational neurology

Published: December 19, 2025

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis.

Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 17, 2025

A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.

A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.

Journal: Brain communications

Published: October 02, 2025

Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis.

Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis.

Journal: European journal of neurology

Published: August 31, 2025

Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.

Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.

Journal: JAMA neurology

Published: June 02, 2025

Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.

Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.

Journal: Therapeutic advances in neurological disorders

Published: April 25, 2025

The relationship between CSF/serum immunoglobulin and albumin ratio across laboratories: a retrospective, multi-center study.

The relationship between CSF/serum immunoglobulin and albumin ratio across laboratories: a retrospective, multi-center study.

Journal: Fluids and barriers of the CNS

Published: April 03, 2025

Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.

Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 18, 2025

Showing 1-12 of 128

Last Updated: 09/26/2026